Janoudi N, et al. - The efficacy of adalimumab as a treatment for fatigue in patients with rheumatoid arthritis (RA) is evaluated in this study. This quasi-experimental study is a good starting point for research on the effectiveness of adalimumab in treating fatigue in RA patients. The outcomes here recommend that a randomized controlled trial evaluating adalimumab as a treatment alternative for RA patients suffering from fatigue is justified.

Methods

• In this study, they monitored fatigue in patients with RA who were already on an adalimumab treatment regimen.
• Fatigue, general well-being, comorbidities, and disease activity were measured at baseline and ∼8, 16, and 24 weeks, thereafter.

Results

• Significant reductions in fatigue scores and disease activity were seen from baseline to 6 months after.
• A predictive regression model of fatigue severity was proposed and was observed to be significant, with RA disease activity as the most significant predictor of fatigue severity.